title: [Blood concentration monitoring during high-dose methotrexate treatment].
abstract: OBJECTIVE
  To explore the clinical value of blood concentration monitoring during high-dose methotrexate (MTX) treatment.
  
  
  METHODS
  High-dose MTX (1.5-9.0 g) was infused to 105 patients with acute lymphoblastic leukemia or lymphoma, and then the blood MTX concentration was measured by fluorescence polarization immune assay (FPIA) 44 hours after the start of administration. The procedure was repeated every 6-12 hours until the concentration was less than 0.1 micromol/L.
  
  
  RESULTS
  Forty-four hours after the start of administration, the blood MTX concentration (C(MTX/44h)) was > or = 5 micromol/L in 6 patients (2.8%) and was between 1 and 5 micromol/L in 23 patients (10.6%). C(MTX/44h) > or = 1 micromol/L was more common in patients received 5.0 g MTX. No severe adverse event was observed in all patients.
  
  
  CONCLUSIONS
  Blood MTX concentration is different after high-dose MTX treatment due to individual metabolic differences, and therefore it is clinically important to monitor blood concentration of MTX. Elimination delay is more common in patients receive 5.0 g MTX. Application of high-dose MTX therapy under the monitoring of blood MTX concentration is safe and feasible.
authors.affiliation: Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors.forename: Li
authors.initials: L
authors.lastname: Jiao
authors.forename: Dao-Bin
authors.initials: DB
authors.lastname: Zhou
authors.forename: Shu-Jie
authors.initials: SJ
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Duan
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.forename: Bing
authors.initials: B
authors.lastname: Han
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.forename: Yong-Qiang
authors.initials: YQ
authors.lastname: Zhao
authors.forename: Ti
authors.initials: T
authors.lastname: Shen
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wang
authors.forename: Min
authors.initials: M
authors.lastname: Ye
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate